Quarterly report pursuant to Section 13 or 15(d)

TSO (Details Textual)

v2.4.0.6
TSO (Details Textual)
 6 Months Ended 72 Months Ended 0 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2011
USD ($)
Jun. 30, 2012
USD ($)
Dec. 31, 2011
USD ($)
Jan. 07, 2011
Ova Med [Member]
USD ($)
Mar. 31, 2012
Ova Med [Member]
USD ($)
Jun. 30, 2012
Ova Med [Member]
USD ($)
Dec. 31, 2011
Ova Med [Member]
USD ($)
Apr. 30, 2012
Falk [Member]
USD ($)
Apr. 30, 2012
Falk [Member]
EUR (€)
Mar. 31, 2012
Falk [Member]
USD ($)
Mar. 31, 2012
Falk [Member]
EUR (€)
Jun. 30, 2012
Falk [Member]
USD ($)
Jun. 30, 2012
Falk [Member]
EUR (€)
Jan. 07, 2011
Asphelia Asset Purchase [Member]
USD ($)
Jun. 30, 2012
Asphelia Asset Purchase [Member]
Dec. 31, 2011
Asphelia Asset Purchase [Member]
USD ($)
TSO (Textual) [Abstract]                                
Date of acquisition                             Jan. 07, 2011  
Payment for purchase of assets                           $ 20,706,000    
Number of Series B Convertible Preferred Stock issued                           2,525,677    
Series B Convertible Preferred Stock issued, per share                           $ 6.38    
PCP Note, principal amount                           750,000    
Cash paid for asset purchase                           3,809,000    
Payment to related party       3,400,000                   61,000,000    
Repayment of Asphelia's debt                           400,000    
Acquired in-process research and development 20,706,000 20,706,000                           20,700,000
Contingent milestone payments to OvaMed             5,400,000                    
Milestone payments to related party         200,000,000   1,500,000     1,400,000 1,000,000          
Current expiry date of Supply Agreement           2014-03                    
Automatic renewal of OvaMed Supply Agreement           1 year                    
Prior notice period for non renewal of OvaMed Supply Agreement           12 months                    
Cash paid to Falk                       6,500,000 5,000,000      
Royalty payable to Falk                       1.00% 1.00%      
Additional payments to Falk               2,000,000 1,500,000              
Remaining amount payable to Falk                       3,300,000 2,500,000      
Accrued Milestones   $ 3,154,000 $ 2,899,000                          
Percentage responsibility for clinical testing                       50.00% 50.00%